{"DataElement":{"publicId":"7587864","version":"1","preferredName":"Inotuzumab Ozogamicin Dose Modification Dose Modifications Inotuzumab Ozogamicin","preferredDefinition":"information related to dose modification._A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora._the coded indicator whether the patient's/participant's initial dose amount was changed.(CDUS Exchange)_Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient._A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","longName":"INO_DOSE_MOD_CD","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7587857","version":"1","preferredName":"Inotuzumab Ozogamicin Dose Modification","preferredDefinition":"information related to dose modification._A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","longName":"INO_DOSE_MOD","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6306958","version":"1","preferredName":"Inotuzumab Ozogamicin Dose","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.:A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","longName":"C71542:C25488","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6D6B8366-079B-5B9A-E053-F662850ABB56","latestVersionIndicator":"Yes","beginDate":"2018-05-30","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-05-30","modifiedBy":"ONEDATA","dateModified":"2018-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177416","version":"1","preferredName":"Modification","preferredDefinition":"Modification; the act of making something different.","longName":"Modification","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Modification","conceptCode":"C25572","definition":"Modification; the act of making something different.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-523A-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC43B312-E5C6-58D5-E053-4EBD850A5B4C","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ARCHERJ","dateModified":"2021-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7587860","version":"1","preferredName":"Dose Modifications Inotuzumab Ozogamicin","preferredDefinition":"the coded indicator whether the patient's/participant's initial dose amount was changed.(CDUS Exchange)_Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient._A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","longName":"INO_DOSMOD","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"2","valueDescription":"Yes, delayed (per protocol dose modifications)","ValueMeaning":{"publicId":"7587862","version":"1","preferredName":"Yes, delayed (per protocol dose modifications)","longName":"7587862","preferredDefinition":"Yes, delayed (per protocol dose modifications)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC43D120-134D-2691-E053-4EBD850A68A0","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC43D120-1366-2691-E053-4EBD850A68A0","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","deletedIndicator":"No"},{"value":"4","valueDescription":"Yes, unplanned omission or delay (not per protocol dose modifications)","ValueMeaning":{"publicId":"7587861","version":"1","preferredName":"Yes, unplanned omission or delay (not per protocol dose modifications)","longName":"7587861","preferredDefinition":"Yes, unplanned omission or delay (not per protocol dose modifications)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC43D120-132A-2691-E053-4EBD850A68A0","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC43D120-1343-2691-E053-4EBD850A68A0","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","deletedIndicator":"No"},{"value":"3","valueDescription":"Yes, omitted (per protocol dose modifications)","ValueMeaning":{"publicId":"7587863","version":"1","preferredName":"Yes, omitted (per protocol dose modifications)","longName":"7587863","preferredDefinition":"Yes, omitted (per protocol dose modifications)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC43D120-1370-2691-E053-4EBD850A68A0","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC43D120-1389-2691-E053-4EBD850A68A0","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","deletedIndicator":"No"},{"value":"1","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC43D120-1393-2691-E053-4EBD850A68A0","beginDate":"2006-02-28","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BCAB6E58-9320-57F9-E053-4EBD850A0811","beginDate":"2006-02-28","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-03-03","modifiedBy":"ONEDATA","dateModified":"2021-03-03","deletedIndicator":"No"},{"value":"Yes, delayed (per protocol dose modifications)","valueDescription":"Yes, delayed (per protocol dose modifications)","ValueMeaning":{"publicId":"7587862","version":"1","preferredName":"Yes, delayed (per protocol dose modifications)","longName":"7587862","preferredDefinition":"Yes, delayed (per protocol dose modifications)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC43D120-134D-2691-E053-4EBD850A68A0","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BCAB6E58-9336-57F9-E053-4EBD850A0811","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-03-03","modifiedBy":"ONEDATA","dateModified":"2021-03-03","deletedIndicator":"No"},{"value":"Yes, omitted (per protocol dose modifications)","valueDescription":"Yes, omitted (per protocol dose modifications)","ValueMeaning":{"publicId":"7587863","version":"1","preferredName":"Yes, omitted (per protocol dose modifications)","longName":"7587863","preferredDefinition":"Yes, omitted (per protocol dose modifications)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC43D120-1370-2691-E053-4EBD850A68A0","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BCAB6E58-934C-57F9-E053-4EBD850A0811","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-03-03","modifiedBy":"ONEDATA","dateModified":"2021-03-03","deletedIndicator":"No"},{"value":"Yes, unplanned omission or delay (not per protocol dose modifications)","valueDescription":"Yes, unplanned omission or delay (not per protocol dose modifications)","ValueMeaning":{"publicId":"7587861","version":"1","preferredName":"Yes, unplanned omission or delay (not per protocol dose modifications)","longName":"7587861","preferredDefinition":"Yes, unplanned omission or delay (not per protocol dose modifications)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC43D120-132A-2691-E053-4EBD850A68A0","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BCAB6E58-9362-57F9-E053-4EBD850A0811","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-03-03","modifiedBy":"ONEDATA","dateModified":"2021-03-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008528","version":"1","preferredName":"Protocol Administration","preferredDefinition":"the management of a research protocol and its case report forms.","longName":"PROT_ADM","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECAD41-A932-34B1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7587859","version":"1","preferredName":"Inotuzumab Ozogamicin Dose Modification","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.:Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient.","longName":"C71542:C54346","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dose Modification","conceptCode":"C54346","definition":"Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC43D120-1306-2691-E053-4EBD850A68A0","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ONEDATA","dateModified":"2021-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC43D120-1317-2691-E053-4EBD850A68A0","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"ARCHERJ","dateModified":"2021-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Was the Inotuzumab Ozogamicin","type":"Preferred Question Text","description":"Was the Inotuzumab Ozogamicin Dose delayed or omitted?","url":null,"context":"COG"},{"name":"COG CRF Text 01","type":"Alternate Question Text","description":"Was Inotuzumab Ozogamicin Dose 1 (intended administration on Day 1) delayed or omitted?","url":null,"context":"COG"},{"name":"COG CRF Text 02","type":"Alternate Question Text","description":"Was Inotuzumab Ozogamicin Dose 2 (intended administration on Day 8) delayed or omitted?","url":null,"context":"COG"},{"name":"COG CRF Text 03","type":"Alternate Question Text","description":"Was Inotuzumab Ozogamicin Dose 3 (intended administration on Day 15) delayed or omitted?","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC43DDD1-43F6-345D-E053-4EBD850A05D0","latestVersionIndicator":"Yes","beginDate":"2021-02-26","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-26","modifiedBy":"MAESKEB","dateModified":"2021-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}